Literature DB >> 33766769

Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.

Hongguang Ma1, Huiqun Wang1, James C Gillespie2, Rolando E Mendez2, Dana E Selley2, Yan Zhang3.   

Abstract

In the present work, we reported the application of a nitrogen-walk approach on developing a series of novel opioid ligands containing an azaindole moiety at the C6-position of the epoxymorphinan skeleton. In vitro study results showed that introducing a nitrogen atom around the indole moiety not only retained excellent binding affinity, but also led to significant functional switch at the mu opioid receptor (MOR). Further computational investigations provided corroborative evidence and plausible explanations of the results of the in vitro studies. Overall, our current work implemented a series of novel MOR ligands with high binding affinity and considerably low efficacy, which may shed light on rational design of low efficacy MOR ligands for opioid use disorder therapeutics.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antagonist; Computational studies; Mu opioid receptor; Nitrogen-walk approach

Mesh:

Substances:

Year:  2021        PMID: 33766769      PMCID: PMC8113153          DOI: 10.1016/j.bmcl.2021.127953

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  20 in total

1.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

Review 2.  Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.

Authors:  Edon Vitaku; David T Smith; Jon T Njardarson
Journal:  J Med Chem       Date:  2014-10-07       Impact factor: 7.446

3.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

4.  Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.

Authors:  Lewis D Pennington; Michael D Croghan; Kelvin K C Sham; Alexander J Pickrell; Paul E Harrington; Michael J Frohn; Brian A Lanman; Anthony B Reed; Matthew R Lee; Han Xu; Michele McElvain; Yang Xu; Xuxia Zhang; Michael Fiorino; Michelle Horner; Henry G Morrison; Heather A Arnett; Christopher Fotsch; Andrew S Tasker; Min Wong; Victor J Cee
Journal:  Bioorg Med Chem Lett       Date:  2011-11-04       Impact factor: 2.823

5.  Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Authors:  Samuel Obeng; Abdulmajeed Jali; Yi Zheng; Huiqun Wang; Kathryn L Schwienteck; Chongguang Chen; David L Stevens; Hamid I Akbarali; William L Dewey; Mathew L Banks; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

6.  Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Jianyang Chen; Shashidhar K Akubathini; Irina O Beletskaya; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2011-07-18       Impact factor: 2.823

7.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

8.  Synthesis and structure-affinity relationships of selective high-affinity 5-HT(4) receptor antagonists: application to the design of new potential single photon emission computed tomography tracers.

Authors:  Emmanuelle Dubost; Noé Dumas; Christine Fossey; Rosa Magnelli; Sabrina Butt-Gueulle; Céline Ballandonne; Daniel H Caignard; Fabienne Dulin; Jana Sopkova de-Oliveira Santos; Philippe Millet; Yves Charnay; Sylvain Rault; Thomas Cailly; Frederic Fabis
Journal:  J Med Chem       Date:  2012-11-09       Impact factor: 7.446

9.  Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.

Authors:  Sumanta Garai; Pushkar M Kulkarni; Peter C Schaffer; Luciana M Leo; Asher L Brandt; Ayat Zagzoog; Tallan Black; Xiaoyan Lin; Dow P Hurst; David R Janero; Mary E Abood; Anaelle Zimmowitch; Alex Straiker; Roger G Pertwee; Melanie Kelly; Anna-Maria Szczesniak; Eileen M Denovan-Wright; Ken Mackie; Andrea G Hohmann; Patricia H Reggio; Robert B Laprairie; Ganesh A Thakur
Journal:  J Med Chem       Date:  2020-01-03       Impact factor: 7.446

10.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.

Authors:  Guo Li; Lindsey C Aschenbach; Jianyang Chen; Michael P Cassidy; David L Stevens; Bichoy H Gabra; Dana E Selley; William L Dewey; Richard B Westkaemper; Yan Zhang
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.